In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ikaria’s Hybrid Business Model Taps Big Pharma Trends

Executive Summary

Although Ikaria focuses on a highly specialized segment of the hospital market, its integrated business model offers insights into continuum of care strategies that pharma companies are evaluating in a reimbursement-focused world. The company’s promising strategy could get a boost from key trial read-outs as soon as late 2012.


Related Content

Moving Beyond Cubicin: Cubist Sets The Stage For Long-Term Growth
The Abbott Split Up: Who Wins?
Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition
Advanced BioHealing To Bring Regeneration To Shire
Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts
The Shake Up At Endo Pharma
Ikaria, NuPathe File Initial Public Offerings
With Second Licensing Deal In A Month, Ikaria Adds To Critical Care Pipeline
Ikaria Backers Buy INO, Create Model for Self-Funding Discovery
Ikaria Inc.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts